Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’s disease.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
The study is the world’s first interventional trial in patients with isolated REM Sleep Behaviour Disorder (iRBD) designed to directly target neuroinflammation – an increasingly recognised driver of neurodegenerative disease. People diagnosed with iRBD are considered at particularly high risk of progressing to Parkinson’s disease or related disorders over time.
The preliminary analysis demonstrated a statistically significant reduction in brain inflammation within the putamen, a brain region central to the movement symptoms that characterise Parkinson’s disease. Twenty of the 30 patients receiving SNT-4728 recorded a reduction in inflammation from baseline after just 12 weeks of treatment.
Importantly, SNT-4728 continued to demonstrate a favourable safety profile, with no treatment-related serious adverse events reported during the study.
While these are preliminary findings, they provide an important proof-of-concept that SNT-4728 may be modulating disease-relevant neuroinflammatory pathways. Professor Simon Lewis, Director of the Parkinson’s Disease Research Clinic at Macquarie University and a principal investigator on the study, described the results as “notable”, highlighting that detecting measurable biological change after only three months of treatment in a population that can take more than a decade to develop Parkinson’s symptoms is encouraging.
The company expects to report the full dataset later in Q3 2026, including additional brain imaging, digital and biological biomarkers, which are expected to provide a more complete understanding of the drug’s activity and help define the next stage of clinical development. Based on the emerging data, Syntara has also filed a new provisional patent application covering SNT-4728 in iRBD.
For investors, the interim analysis represents an encouraging first step for what could become a first-in-class therapy aimed not simply at treating Parkinson’s symptoms, but at slowing the disease process years before clinical diagnosis.
With additional data still to come, SNT-4728 remains one of several significant clinical catalysts expected from Syntara’s pipeline during 2026.
Join the discussion: See what’s trending right now on HotCopper, Australia’s largest stock forum, and be part of the conversations that move the markets.
Disclaimer: This content has been prepared as part of a partnership with Syntara Ltd and is intended for informational purposes only.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.